Lumentum InP Shortage and Marvell Deal Dynamics

Lumentum InP Shortage and Marvell Deal Dynamics

Driven
·Agent created by Agent
Driven·Agent created by Agent
Indium phosphide substrate shortages are reportedly constraining supply, while Lumentum’s capacity is said to be booked through 2029. What does this imply for its production, pricing power, and growth outlook?

Conclusion: The indium phosphide (InP) squeeze is real and gives Lumentum (LITE) unusual pricing power and near-term visibility. But the "booked through 2029" framing overstates the evidence, and since Nov 2, 2026, LITE shareholders no longer own a standalone growth story. Marvell's all-stock acquisition, announced that day, means LITE now trades as a levered proxy for the Marvell deal, with the deal expected to close in the first half of 2028. For the stock, the shortage matters mainly through its effect on Marvell's combined business and on deal-spread risk.

Data as of: LITE and MRVL closes on Tue, Nov 17, 2026 (16:00 New York time). Company results are from the Nov 2, 2026 fiscal Q1 FY2027 release. News runs through Nov 15, 2026.

1. Is the premise accurate?

Partly. The sources do not say capacity is "booked through 2029."

  • At an Oct 2026 Tokyo event, CEO Michael Hurlston said the company is "completely sold out" and demand is outstripping supply "well into early 2029." He also said it cannot meet about 70% of demand for some products through 2027, with shortfalls for some other products lasting through 2028 (Qz, Oct 9, 2026, citing Bloomberg).
  • Some headlines say "sold out through 2029," and one German aggregator says the order book runs to 2030. I could not verify the 2030 claim, so I treat it as unverified.
  • The best reading: demand exceeds supply into early 2029, with the gap narrowing for some products by 2028. That is still a strong statement, but it is a supply shortfall, not a fully booked contract book.

2. Production: capacity is growing fast but still short

  • Lumentum runs five InP fabs. In July 2026 Hurlston said it still ships more than 30% below what customers want (). On the May call he said the supply line would grow about 50% from one December quarter to the next (same source, ).
  • The Tokyo-area plant has been scaled up twelvefold over two years, and the company plans at least $350 million of investment there and at a neighboring site. Hyperscalers have agreed to take on some of the capital risk (). Bloomberg, via Qz, says new InP capacity takes three to five years to build.
  • Upstream supply is tight too. Lumentum agreed to pay AXT $43.5 million upfront and another $43.5 million later, a total of in capacity-reservation deposits, for a minimum annual commitment running through (). Lumentum is therefore paying up to secure substrate, which is a cost-side constraint.
  • Indium supply is concentrated. China held an estimated 69% of primary refined indium in 2025, and export permits govern substrate shipments from China. A USGS-based figure cited by Tom's puts the 2025 average US warehouse price at , up from in 2024.

Assessment: Production is supply-capped, and the constraint is physical (wafers and fab ramp time), not demand. Capacity should grow, but only at the pace of the 6-inch wafer transition and new fabs. Fab 5 in North Carolina is expected to ramp around 2028.

3. Pricing power: evident, but not cleanly separable

  • Customers are ordering further ahead and paying substantial deposits, and inventories are tightening, pushing prices higher ().
  • Non-GAAP gross margin rose to in fiscal Q1 2027 from a year earlier, a increase. Management attributed the gain to pump lasers and optical circuit switches, with cloud modules improving. The release does not split out price versus mix versus volume, so pricing power is an inference, not a disclosed figure.
  • Operating leverage is strong. Non-GAAP operating margin reached , and guidance for fiscal Q2 is .

Assessment: Pricing power is real in the sense that buyers pay deposits and accept allocation. The margin expansion is consistent with that, but it also reflects mix shifts that could reverse. The margin path is the main thing to monitor.

4. Growth outlook: strong near-term, contingent on supply

  • Fiscal Q1 2027 net revenue was , up year over year.
  • Fiscal Q2 guidance is $1.575 billion to $1.625 billion. The midpoint implies about sequential growth. Non-GAAP diluted EPS guidance is .
  • Management cites a second NPO/CPO win backed by purchase commitments exceeding $5 billion and optical switching as a potential multi-billion-dollar revenue stream. These are company claims, not audited figures.
  • Cash fell by in the quarter to . The release also reports a GAAP net loss for fiscal Q4 2026. I did not verify its cause, so check the 10-Q before relying on it.

Counterpoints:

  • LightCounting's April 2026 forecast expects transceiver shortages to ease by end-2026, as cited by Tom's Hardware. That conflicts with management's view and is a key disagreement to track.
  • Coherent, the other major InP supplier, reports its own 6-inch capacity doubling and backlog into 2028.

5. The Marvell deal changes the investment question

  • On Nov 2, 2026, Marvell agreed to acquire Lumentum in an all-stock deal. Each LITE share converts into MRVL shares. The implied enterprise value is , or about per share, a premium to the unaffected price on Oct 28, 2026. Closing is expected in the (; ).
  • Marvell said the deal is expected to be accretive to its non-GAAP EPS in year one post-close and to offer more than $1 billion in annual run-rate cost synergies. Those are company projections.
  • Current values: MRVL closed at , so 4.5 × MRVL = . LITE closed at . The gap to the exchange-ratio value is about . That spread reflects deal-completion risk and the time to a 2028 close, and it suggests the market is pricing a meaningful chance the deal does not close on these terms.
  • LITE is its 52-week high of .

6. What it implies

  • Production: Supply-constrained through at least 2027 for some products. Growth depends on wafer-size transitions and new fabs, not on demand.
  • Pricing power: Credible, supported by deposits, allocation, and margin expansion. Not yet isolated from mix in disclosures. Input costs (indium, substrates) are rising too, so the spread could narrow if costs catch up.
  • Growth outlook: Strong through fiscal 2027 on guidance. Longer-term growth rests on capacity execution and on whether the LightCounting view proves right.
  • For LITE shareholders: The stock now largely tracks MRVL's share price times 4.5, plus the spread. Lumentum's standalone supply story still matters, because it drives Marvell's expected economics, but it no longer sets LITE's price on its own. The key risks are deal completion, MRVL's share price, and whether the shortage eases faster than management expects.

More research on LITE